During the outbreak of COVID-19 in late 2019, there was widespread interest in the repurposing of most anticancer drugs as potential inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike and host angiotensin-converting enzyme 2 (ACE2) interactions as a strategy to prevent viral transmission [13, 14]. The gene discussed is ACE2; the disease is COVID-19.